Solid Dosage
Diabetes
GEA designs, produces and delivers innovative, integrated solutions for every stage of the manufacturing process of anti-diabetic drugs
Manufacturing Anti-Diabetics to Meet the Needs of the Growing Diabetes Market
With diabetes and the global anti-diabetes drug market on the rise, demand for GEA technologies for the production of these life-saving drugs is already high and set to increase, particularly in new markets and emerging economies
It is estimated that approximately 6.4% of the adult population worldwide has diabetes, leading to a huge demand for oral anti-diabetes drugs. To be able to cater for this demand, high-volume or mass production of these medicines is a fundamental requirement. It enables companies to produce goods faster and reduce the overall per unit production cost, allowing them to make anti-diabetes medications available to less-developed countries.
GEA has been instrumental in designing, producing and delivering innovative, integrated solutions for every stage of the manufacturing process: from materials handling to tablet coating, automation and monitoring. We continue to support this high-volume batch-based production with ongoing improvements and innovative developments.
One example is our range of double-sided tablet presses to accommodate the fact that many oral anti-diabetes medicines are bilayer combination drugs, consisting of two separate layers for each API.
Another trend that we have observed is the move towards continuous manufacturing (CM). Providing increased yields, lower utility consumption and reduced waste, CM meets the industry’s demands for improved production economics and increased manufacturing flexibility.
Focusing on quality during the whole product lifecycle and decreasing any associated risks, GEA is helping its customers to develop, evaluate and optimize continuous processing techniques to enable them to bring new products to market faster and cheaper.
Prodotti e tecnologie
Visualizzazione di 4 su 25
Automazione di processo
Ci occupiamo di integrazione di sistemi, e per farlo integriamo i prodotti software forniti dai leader di mercato con le conoscenze che abbiamo acquisito nel campo della tecnologia di processo e dell'ingegneria degli impianti.
Contained Materials Handling Systems
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
Continuous Direct Compression Line
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Granulation Lines
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
Downloads
Approfondimenti GEA
Kytero 10 I grandi cambiamenti iniziano in piccolo
Con GEA kytero 10, i ricercatori e gli sviluppatori dei settori biofarmaceutico, alimentare e New Food hanno ora a disposizione un potente acceleratore di ultima generazione.
Fueling the circular economy in shipping
Ports now compete not just on logistics, but on sustainability. At Greece’s Piraeus port, an advanced processing and recovery facility recycles ship waste oil into fuel. Equipped with GEA’s high-performance centrifuges, it sets a new benchmark for state-of-the-art, environmentally responsible port operations.
Uova più sostenibili sulle nostre tavole
GEA aiuta i clienti a testare e sviluppare prodotti e ingredienti alternativi alle uova realizzati con la fermentazione di precisione.
